Parker Investment Management LLC Sells 3,205 Shares of Eli Lilly and Company $LLY

Parker Investment Management LLC lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 63.8% during the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 1,819 shares of the company’s stock after selling 3,205 shares during the period. Eli Lilly and Company accounts for about 0.2% of Parker Investment Management LLC’s portfolio, making the stock its 25th largest position. Parker Investment Management LLC’s holdings in Eli Lilly and Company were worth $1,418,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in LLY. Cercano Management LLC lifted its position in Eli Lilly and Company by 15,627.0% during the 2nd quarter. Cercano Management LLC now owns 173,783 shares of the company’s stock worth $135,469,000 after buying an additional 172,678 shares in the last quarter. Jensen Investment Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth about $161,060,000. Intech Investment Management LLC lifted its position in shares of Eli Lilly and Company by 18.9% during the second quarter. Intech Investment Management LLC now owns 168,692 shares of the company’s stock worth $131,500,000 after purchasing an additional 26,857 shares in the last quarter. Sculati Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 16.4% during the second quarter. Sculati Wealth Management LLC now owns 2,131 shares of the company’s stock worth $1,661,000 after purchasing an additional 300 shares in the last quarter. Finally, Cetera Investment Advisers grew its stake in shares of Eli Lilly and Company by 3.1% during the second quarter. Cetera Investment Advisers now owns 253,839 shares of the company’s stock valued at $197,876,000 after purchasing an additional 7,552 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on LLY. Sanford C. Bernstein restated an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, November 3rd. Loop Capital set a $950.00 target price on Eli Lilly and Company in a research report on Monday, November 10th. Daiwa America lowered Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a research note on Sunday, August 17th. Scotiabank initiated coverage on Eli Lilly and Company in a research report on Thursday. They issued a “sector outperform” rating and a $1,165.00 price objective for the company. Finally, BMO Capital Markets upped their target price on shares of Eli Lilly and Company from $930.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Three analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and seven have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $1,015.11.

Eli Lilly and Company Trading Up 0.2%

NYSE LLY opened at $1,024.67 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,033.62. The stock has a 50-day simple moving average of $826.89 and a 200 day simple moving average of $780.14. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $968.70 billion, a PE ratio of 66.97, a P/E/G ratio of 1.21 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion during the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company’s revenue for the quarter was up 53.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.